Last Updated: Friday, January 25, 2013, 12:56
Net sales of the company rose to Rs 634.22 crore for the third quarter, as against Rs 516.59 crore during the same period of 2011-12 fiscal.
Last Updated: Tuesday, January 8, 2013, 14:59
Biotechnology major Biocon on Tuesday said it has received approval from drug controller DCGI to market its product 'Itolizumab', used in the treatment of psoriasis.
Last Updated: Friday, November 16, 2012, 15:04
Biotechnology major Biocon on Friday said it has entered into an agreement with Bristol-Myers Squibb for it's oral insulin new drug candidate IN-105.
Last Updated: Sunday, November 4, 2012, 12:02
The company, which was earlier working actively to list Syngene, said it will not happen this fiscal due to economic, global and political uncertainties.
Last Updated: Wednesday, October 31, 2012, 19:43
As per the agreement, GE Equity International Mauritius, a subsidiary of GE Capital Corporation will make a primary equity investment in Syngene, a joint statement said.
Last Updated: Wednesday, October 31, 2012, 12:15
The net sales of the company rose to Rs 592.40 crore for the second quarter from Rs 505.39 crore in the same period of 2011-12 fiscal.
Last Updated: Saturday, October 27, 2012, 21:07
Opposing the GM (Genetically Modified) crop technology would take the country on a wrong path, Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said on Saturday.
Last Updated: Friday, September 14, 2012, 18:58
Drug firm Biocon Friday said its Malaysia-based subsidiary has inked a pact with Manipal Education Malaysia to collaborate for development of human capital for the biotechnology industry.
Last Updated: Friday, July 27, 2012, 16:36
Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has turned down request from major pharma firms, including, Eli Lilly and Biocon, to increase price of insulin used for diabetes treatment.
Last Updated: Thursday, July 26, 2012, 12:31
Biotechnology major Biocon on Thursday said its consolidated net profit rose 12.49 percent to Rs 78.80 crore for the first quarter ended June 30, 2012.
Last Updated: Sunday, July 15, 2012, 12:30
Biotech major Biocon is planning to forge partnerships as well as leverage existing alliances to augment the access and penetration of its biosimilar molecules.
Last Updated: Tuesday, May 8, 2012, 17:48
Pharma major Biocon has said market value of the portfolio of drugs that are part of its collaboration with US-based Mylan is worth a whopping USD 33 billion (above Rs 1,75,000 crore).
more videos >>
